SBIR Phase I: Continuous Manufacturing for Nucleic Acid Lipid Nanoparticles to Improve the Supply Chain of Therapeutics and Vaccines (COVID-19)
- Funded by National Science Foundation (NSF)
- Total publications:0 publications
Grant number: 2151477
Grant search
Key facts
Disease
COVID-19Start & end year
20222022Known Financial Commitments (USD)
$256,000Funder
National Science Foundation (NSF)Principal Investigator
Antonio CostaResearch Location
United States of AmericaLead Research Institution
DIANT PHARMA INCResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Therapeutics logistics and supply chains and distribution strategies
Special Interest Tags
Innovation
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
The broader impact /commercial potential of this Small Business Innovation Research (SBIR) Phase I project addresses the need for advanced manufacturing technology that can produce future therapeutics and vaccines. Future clinical treatments will rely on continuous manufacturing to meet demand, both with respect to volume and drug product personalization. This project will incorporate continuous manufacturing principles and process analytical sensors and technology. These processes will enable faster responses to global health crises, such as the COVID-19 pandemic.
This Small Business Innovation Research (SBIR) Phase I project will develop a compact, end-to-end, advanced manufacturing system for nucleic acid lipid nanoparticles. This new system will follow current Good Manufacturing Practice (cGMP) and will support end-to-end manufacturing by connecting to a nucleic acid assembly system and a fill-finish system to produce injectable-ready materials. One major goal of this research is to advance the understanding of nanoparticle drug delivery to enable manufacturing injectable ready materials on demand and on-site.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
This Small Business Innovation Research (SBIR) Phase I project will develop a compact, end-to-end, advanced manufacturing system for nucleic acid lipid nanoparticles. This new system will follow current Good Manufacturing Practice (cGMP) and will support end-to-end manufacturing by connecting to a nucleic acid assembly system and a fill-finish system to produce injectable-ready materials. One major goal of this research is to advance the understanding of nanoparticle drug delivery to enable manufacturing injectable ready materials on demand and on-site.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.